Publications
Detailed Information
Effect of ritonavir-boosting on atazanavir discontinuation due to jaundice in HIV-infected Koreans
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choe, P.G. | - |
dc.contributor.author | Park, W.B. | - |
dc.contributor.author | Song, K.-H. | - |
dc.contributor.author | Bang, J.-H. | - |
dc.contributor.author | Kim, E.S. | - |
dc.contributor.author | Park, S.-W. | - |
dc.contributor.author | Kim, H.B. | - |
dc.contributor.author | Kim, N.J. | - |
dc.contributor.author | Oh, M.-D. | - |
dc.contributor.author | Choe, K.W. | - |
dc.date.accessioned | 2024-04-26T01:08:24Z | - |
dc.date.available | 2024-04-26T01:08:24Z | - |
dc.date.created | 2023-05-01 | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Infection and Chemotherapy, Vol.44 No.3, pp.175-179 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199736 | - |
dc.description.abstract | Background: Data regarding differences of intolerance between a ritonavirunboosted and a ritonavir-boosted atazanavir regimen in HIV-infected Koreans is limited. Materials and Methods: A review was conducted of the incidence of severe hyperbilirubinemia (serum total bilirubin ≥3.1 mg/dL) and discontinuation of atazanavir in HIV-infected patients who had received an atazanavir-containing regimen at Seoul National University Hospital from 2005 to 2009. Patients with active liver disease were excluded from the study. Results: Of a total of 335 patients receiving an atazanavir-containing regimen, 145 (43.3%) received treatment with a ritonavir-boosted regimen. The cumulative incidence of severe hyperbilirubinemia at three months was 40.5% in patients receiving a ritonavir-boosted atazanavir regimen and 21.4% in patients receiving an un-boosted atazanavir regimen (P≤0.001). The cumulative incidence of severe hyperbilirubinemia at 12 months was 58.5% in patients receiving a ritonavirboosted regimen and 41.3% in those receiving an un-boosted regimen (P=0.008). The proportion of drug discontinuation due to jaundice during the 12-month period was 11.7% in patients receiving a ritonavir-boosted regimen and 5.3% in those receiving an un-boosted regimen (P=0.035). Conclusions: Occurrence of severe hyperbilirubinemia and discontinuation of atazanavir due to jaundice was significantly more common in HIV-infected Koreans who received a ritonavir-boosted atazanavir regimen than in those who received a ritonavir- un-boosted atazanavir regimen. © 2012 by The Korean Society of Infectious Diseases. | - |
dc.language | 한국어 | - |
dc.publisher | Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy | - |
dc.title | Effect of ritonavir-boosting on atazanavir discontinuation due to jaundice in HIV-infected Koreans | - |
dc.type | Article | - |
dc.identifier.doi | 10.3947/ic.2012.44.3.175 | - |
dc.citation.journaltitle | Infection and Chemotherapy | - |
dc.identifier.scopusid | 2-s2.0-84867059637 | - |
dc.citation.endpage | 179 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 175 | - |
dc.citation.volume | 44 | - |
dc.identifier.kciid | ART001672913 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Park, W.B. | - |
dc.contributor.affiliatedAuthor | Kim, H.B. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | Atazanavir | - |
dc.subject.keywordAuthor | HIV | - |
dc.subject.keywordAuthor | Hyperbilirubinemia | - |
dc.subject.keywordAuthor | Jaundice | - |
dc.subject.keywordAuthor | Ritonavir | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.